I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

Does the MarketBeat Community favor IMAB or BNTC?

Benitec Biopharma received 135 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 65.67% of users gave Benitec Biopharma an outperform vote while only 65.26% of users gave I-Mab an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 62 65.26%	Underperform Votes 33 34.74%
Benitec Biopharma	Outperform Votes 197 65.67%	Underperform Votes 103 34.33%

Do analysts rate IMAB or BNTC?

I-Mab currently has a consensus target price of $5.50, indicating a potential upside of 545.31%. Benitec Biopharma has a consensus target price of $24.71, indicating a potential upside of 77.80%. Given I-Mab's stronger consensus rating and higher possible upside, equities analysts clearly believe I-Mab is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Is IMAB or BNTC more profitable?

I-Mab's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Benitec Biopharma	N/A	-44.61%	-41.25%

Do institutionals & insiders believe in IMAB or BNTC?

38.4% of I-Mab shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 1.3% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the media favor IMAB or BNTC?

In the previous week, Benitec Biopharma had 3 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Benitec Biopharma and 0 mentions for I-Mab. I-Mab's average media sentiment score of 1.93 beat Benitec Biopharma's score of 1.35 indicating that I-Mab is being referred to more favorably in the media.

Company	Overall Sentiment
I-Mab	Very Positive
Benitec Biopharma	Positive

Which has better earnings & valuation, IMAB or BNTC?

Benitec Biopharma has lower revenue, but higher earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.27M	21.22	-$206.44M	N/A	N/A
Benitec Biopharma	$80K	4,074.61	-$21.75M	-$1.51	-9.21

Which has more volatility and risk, IMAB or BNTC?

I-Mab has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Summary

I-Mab and Benitec Biopharma tied by winning 8 of the 16 factors compared between the two stocks.